Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 32.7M 28.24M 26.54M 24.14M 45.38M 3.13B 46.13M 311M 122M 1.57B 123M 120M 5.2B P/E 2026 *
7.43x
P/E 2027 * -1.54x
Enterprise Value 32.7M 28.24M 26.54M 24.14M 45.38M 3.13B 46.13M 311M 122M 1.57B 123M 120M 5.2B EV / Sales 2026 *
2.8x
EV / Sales 2027 * -
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
08-08 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-30 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-30 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-09 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-07 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-31 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
1 day+7.90%
1 week+30.42%
Current month+24.27%
1 month+13.06%
3 months-16.80%
6 months-6.31%
Current year-23.53%
1 week 0.76
Extreme 0.76
1.09
1 month 0.74
Extreme 0.735101
1.09
Current year 0.74
Extreme 0.735101
1.53
1 year 0.74
Extreme 0.735101
1.81
3 years 0.74
Extreme 0.735101
10.24
5 years 0.74
Extreme 0.735101
15.12
10 years 0.74
Extreme 0.735101
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25 Tax

Chief Executive Officer

120,900 0.3876%
31/03/25 Issuer sale

Chief Financial Officer

706,588 2.2650%
31/03/25 Issuer sale

Chief Executive Officer

2,385,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
+7.90%+30.42%-38.46%-83.95% 32.7M
-1.90%+2.85%+62.82%+104.13% 70.07B
-3.21%-4.32%+31.85%+57.27% 52.87B
-2.05%-5.61%-3.18%+449.71% 27.02B
-1.27%-1.57%+45.90%+8.25% 23.61B
+1.05%-0.62%-18.00%-11.93% 23.38B
+3.81%+20.97%+266.37%+531.28% 19.43B
+0.10%+1.40%+35.36%-19.94% 18.75B
-0.95%-3.52%+19.93%+594.00% 15.85B
+1.24%-5.23%+33.75%+137.66% 12.7B
Average +0.47%+4.00%+43.63%+176.65% 26.37B
Weighted average by Cap. -1.09%+0.56%+50.22%+164.96%

Financials

2026 *2027 *
Net sales 11.67M 10.08M 9.47M 8.61M 16.19M 1.12B 16.46M 111M 43.38M 559M 43.8M 42.85M 1.86B -
Net income 4.91M 4.24M 3.98M 3.62M 6.81M 469M 6.92M 46.66M 18.24M 235M 18.42M 18.02M 781M -31.71M -27.39M -25.73M -23.4M -44M -3.03B -44.73M -302M -118M -1.52B -119M -116M -5.05B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
27
Date Price Change Volume
14/08/26 $1.040 +7.90% 490,513
13/08/26 $0.9639 +17.39% 284,682
12/08/26 $0.8211 +3.53% 240,645
11/08/26 $0.7931 +2.97% 168,769
10/08/26 $0.7702 -3.41% 177,304
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.040USD
Average target price
3.500USD
Spread / Average Target
+236.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock